



MICROMEDEX® 2.0 臨床醫藥資訊檢索運用

碩睿資訊有限公司.

Max Lin 林庚賢

Sales Executive

max@sris.com.tw



THOMSON REUTERS

Overview



Drug Information	Disease Information
<u>DRUGDEX® System</u> <u>DRUG-REAX® System</u> <u>MARTINDALE</u> <u>Index Nominum</u> <u>Physicians' Desk</u> <u>Reference®(PDR®)</u> <u>P & T QUIK® Reports</u> <u>IV INDEX® System</u> <u>MSDS</u> <u>IDENTIDEX® System</u> <u>Red Book® Online</u> <u>KINETIDEX® System</u>	<u>DISEASEDEX™ General Medicine</u> <u>DISEASEDEX™ Emergency Med.</u> <u>Lab adviser™</u>
	Patient Education
	<u>AltCareDex® Alternative Medicine</u> <u>Education</u> <u>CareNotes™ System</u>
	Toxicology Information
	<u>POISINDEX® System</u> <u>TOMES® System</u> <u>REPRORISK® System</u>
Alternative Medicine	Free Resources
<u>AltMedDex® System</u> <u>AltMedDex® Protocols</u> <u>Herbal Medicines</u>	<u>Calculators</u> <u>mobileMICROMEDEX™ System</u>



Martindale

IBUPROFEN

Physical And Pharmaceutical Properties
Proprietary Names

IBUPROFEN LYSINE

Physical And Pharmaceutical Properties

PROPRIETARY NAMES

PHYSICOCHEMICAL CHARACTERISTICS

Stability.

ADVERSE EFFECTS, TREATMENT, AND PRECAUTIONS

Breast feeding.
Children.
Effects on the blood.
Effects on the cardiovascular system.
Effects on the CNS.
Effects on electrolytes.
Effects on the eyes.
Effects on the gastrointestinal tract.
Effects on the kidneys.
Effects on the liver.
Effects on the skin.
Hypersensitivity.
Meningitis.
Overdosage.

INTERACTIONS

Antineoplastics.
Aspirin.
Lipid regulating drugs.
Muscle relaxants.

PHARMACOKINETICS

USES AND ADMINISTRATION

Administration in children.
Cachexia.
Cystic fibrosis.
Pain.

Ibuprofen

MARTINDALE - The Complete Drug Reference

OTHER SOURCES

Print

Expand All | Collapse All | Top of Page

See also [Analgesics Anti-inflammatory Drugs and Antipyretics](#)

Ibuprofen

Physical And Pharmaceutical Properties

- Name Status: BAN, USAN, rINN
- Synonyms: Ibuprofeeni; Ibuprofén; Ibuprofenas; Ibuprofène; Ibuprofeno; Ibuprofenum; RD-13621; U-18573
- Chemical Name: 2-(4-Isobutylphenyl)propionic acid
- Molecular Formula: C₁₃H₁₈O₂
- Molecular Weight: 206.3
- CAS Registry: 15687-27-1
- Pharmacopoeias: In Chin., Eur. (see [About Martindale](#)), Int., Jpn, US, and Viet.
- Ph. Eur. 7.2 (Ibuprofen). A white or almost white, crystalline powder or colourless crystals. M.p. 75° to 78°. Practically insoluble in water; freely soluble in acetone, in dichloromethane, and in methyl alcohol; it dissolves in dilute solutions of alkali hydroxides and carbonates.
- USP 34 (Ibuprofen). A white to off-white crystalline powder having a slight characteristic odour. Practically insoluble in water; very soluble in alcohol, in acetone, in chloroform, and in methyl alcohol; slightly soluble in ethyl acetate. Store in airtight containers.
- ATC: C01EB16; G02CC01; M01AE01; M02AA13

Proprietary Names

- Abbifen (Abbott, S.Afr.) ,ABKI (Química y Farmacia, Mex.) ,Aches-N-Pain (Lederle, USA) ,Acks (BPL, India) ,ACT-3 (Whitehall Consumer, Austral.) ,ACT-3 (Wyeth Consumer, NZ) ,Actifen (Sterling Health, Spain) ,Actimidol (Sterling Health, Spain) ,Actiprofen (Bayer, Canad.) ,Actinofen (GSK Consumer, Austral.) ,Actinofen (Sanofi-Aventis, Braz.) ,Actinofen (SmithKline Beecham, Ind.) ,Actron (Bayer



Index Nominum

Ibuprofen (Rec.INN)

Index Nominum 

[Index Nominum Abbreviations Key](#)

Foreign Names

L: Ibuprofenum
D: Ibuprofen
F: Ibuprofène
S: Ibuprofeno

ATC

C01EB16, C01EB16, G02CC01, M01AE01, M02AA13

Therapeutic Category

 Analgesic, antipyretic and anti-inflammatory agent
 Non-steroidal anti-inflammatory drug, NSAID

Chemical Name

 (R,S)-2-(4-Isobutylphenyl)propionsäure [IUPAC]
 Benzeneacetic acid, α -methyl-4-(2-methylpropyl)-
 α -p-Isobutylphenylpropionic acid [WHO]

CAS Number

0015687-27-1

Chemical Formula

C₁₃H₁₈O₂


Ibuprofen (Rec.INN)

Index Nominum 

Mol. wt.

206.28

Structure of Ibuprofen



Synonyms

OS: Ibuprofen [BAN, JAN, USAN]
OS: Ibuprofene [DCIT]
OS: Ibuprofène [DCF]
IS: RD 13621
IS: U 18573 (Upjohn)
IS: UCB 79171 (UCB)
IS: VUFB 201282
IS: VUFB 9649
PH: Ibuprofen [BP 2010, Ph. Eur. 6, Ph. Int. 4, USP 32, JP XIV]
PH: Ibuprofène [Ph. Eur. 6]
PH: Ibuprofenum [Ph. Int. 4, Ph. Eur. 6]
Acatar® Zatoki [+ pseudoephedrine hydrochloride] US Pharmacia, PL
ACT-3® Wyeth Consumer Healthcare, NZ
Actron® Bayer, AR
Actron® Bayer, CL
Actron® Bayer, MX
Acuifem® Gezzi, AR
Adax® K2 Pharmavida, PE

Detailed drug information of the consumer

BLACK BOX WARNING

BRAND NAMES/AVAILABLE DOSAGE FORMS

CLASSES

USES FOR THIS MEDICINE

BEFORE RECEIVING THIS MEDICINE

PROPER USE OF THIS MEDICINE

PRECAUTIONS WHILE RECEIVING THIS MEDICINE

SIDE EFFECTS OF THIS MEDICINE

IBUPROFEN (Intravenous route) **eye-bue-PROE-fen**

Detailed Drug Information for the Consumer™ 

 Print

 Expand All |  Collapse All |  Top of Page

▼ Uses for This Medicine

- Ibuprofen injection is a nonsteroidal antiinflammatory drug (NSAID) that is used alone or together with other medicines (e.g., opioid analgesics) to relieve mild to severe pain. It is also used to treat fever in adults.
- This medicine is available only with your doctor's prescription.

▼ Before Receiving This Medicine

- In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies—

- Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric—

- Appropriate studies have not been performed on the relationship of age to the effects of ibuprofen injection in children and teenagers below 17 years of age. Safety and efficacy have not been established.

Geriatric—

- Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of ibuprofen injection in the elderly. However, elderly patients are more likely to have age-related kidney, liver, heart, or stomach problems, which may require an adjustment in the dose for patients receiving ibuprofen injection.

Pregnancy—



P &T Quik

Ibuprofen Injection (Sep 2009)



P&T QUIK®

Top of Page

GENERIC NAME: IBUPROFEN INJECTION

PROPRIETARY NAME: CALDOLOR(TM)/CUMBERLAND

FORMULARY RECOMMENDATION:

Ibuprofen injection should be added to the formulary for the treatment of pain and fever in hospitalized adult patients unable to receive oral therapy.

FDA APPROVED INDICATIONS (1):

- Management of mild to moderate pain in adults and the management of moderate to severe pain as an adjunct to opioid analgesics. - Reduction of fever in adults.

PHARMACOLOGY (1-3):

Ibuprofen is a propionic acid derivative nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activity. While its exact mechanism of action is not completely understood, ibuprofen is a nonselective inhibitor of cyclooxygenase (COX), the enzyme that catalyzes the synthesis of cyclic endoperoxidases from arachidonic acid to form prostaglandins.

EFFICACY (1):

SUMMARY:

The effectiveness of ibuprofen injection in the treatment of acute pain was established in a randomized, double-blind, placebo-controlled clinical trial involving 319 adult patients undergoing an elective abdominal hysterectomy. Results from this study showed that patients receiving ibuprofen injection reported a significant reduction in post-surgical pain intensity within the first 24 hours while also significantly reducing their use of morphine for pain on an as-needed basis compared to those receiving a placebo. The efficacy of ibuprofen as an antipyretic was demonstrated in two randomized, double-blind clinical trials involving 180 hospitalized febrile adult patients. Results from these studies showed that patients treated with ibuprofen experienced a significant reduction in temperature as compared to those receiving a placebo. Clinical comparisons between ibuprofen injection and ketorolac injection are not available.

PAIN MANAGEMENT - ABDOMINAL HYSTERECTOMY

CONCLUSION (1):

Ibuprofen injection is effective in the treatment of pain in adults.

STUDY DESIGN:



From Drug To Disease

▼ Disease Information (93)

藥物治療...(93)

- Abdominal pain
- Abnormal vaginal bleeding
- Acromioclavicular separation
- Adhesive capsulitis of shoulder

More ▶

DEFINITION

Abdominal pain

 [Display Entire Document](#) |  [Print](#)

FINDINGS

DISEASEDEX™ General Medicine Summary 

OTHER SOURCES ▶

DIFFERENTIAL DIAGNOSIS

TREATMENT

 [Expand All](#) |  [Collapse All](#) |  [Top of Page](#)

TESTING

TREATMENT

- Drug Therapy
- Procedural Therapy
- Non-Procedural Therapy

REFERENCE

IBUPROFEN

(Related toxicological information in IBUPROFEN)

Adults: 200 to 800 mg orally every 6 to 8 hours as needed (maximum 3.2 g/day) [34]

Pediatrics: 5 to 10 mg/kg orally every 6 to 8 hours as needed (maximum, lesser of 40 mg/kg/day or 2.4 g/day) [35]

ACETAMINOPHEN/OXYCODONE HYDROCHLORIDE

Adults: Oxycodone 5 to 20 mg/acetaminophen 325 to 1,000 mg orally every 4 hours as needed (maximum 4 g acetaminophen/day) [34]

Pediatrics: 0.05 to 0.15 mg/kg of the oxycodone ingredient orally every 4 hours as needed [35][36]

HYDROCODONE BITARTRATE/ACETAMINOPHEN

Adults: Hydrocodone 5 to 20 mg/acetaminophen 325 to 1,000 mg orally every 4 hours as needed (maximum 4 g acetaminophen/day) [34]

Pediatrics (2-13 years): 0.27 mL/kg (0.135 mg/kg hydrocodone and 9 mg/kg acetaminophen) orally every 4 hours as needed (maximum 6 doses/day)

Clinical Checklist

▼ Clinical Checklist (2)

通常使用於...(1)

■ Cystic fibrosis

ALWAYS DO

Treatment

NEVER DO

Treatment

RELATED INFORMATION

Conditions

Drugs

Toxicology

Studies and Alerts

REFERENCES

Cystic fibrosis

✓ Clinical Checklist™ 

 Print

 Expand All |  Collapse All |  Top of Page

▼ Always Do

Treatment

Drug Therapies

Strength of
Recommendation/Evidence

Performance
Measure

Prescribe the chronic use of inhaled tobramycin to improve lung function and reduce exacerbations in patients with cystic fibrosis, 6 years of age and older, who have moderate to severe lung disease (Category A), or who are asymptomatic or have mild lung disease (Category B), and with *Pseudomonas aeruginosa* persistently present in cultures of the airways [1].

I A

Prescribe azithromycin for chronic use to improve lung function and to reduce exacerbations in patients with cystic fibrosis, 6 years of age and older, who have *Pseudomonas aeruginosa* persistently present in cultures of the airways [1].

I B

Prescribe the chronic use of inhaled dornase alfa (recombinant human DNase) to improve lung function and reduce exacerbations in patients with cystic fibrosis, 6 years of age and older, who have moderate to severe lung disease (Category A), or who are asymptomatic or have mild lung disease (Category B), and with *Pseudomonas aeruginosa* persistently present in cultures of the airways [1].

I A

Prescribe the chronic use of inhaled hypertonic saline to improve lung function and to reduce exacerbations in patients with cystic fibrosis aged 6 years and older [1].

I B


Prescribe inhaled beta₂ adrenergic receptor agonists for chronic use to improve lung function in patients with cystic fibrosis aged 6 years and older [1].

I B

Prescribe the chronic use of oral ibuprofen to slow the loss of lung function in patients with cystic fibrosis, 6 years of age and older, with FEV₁ measurements greater than 60% predicted [1].

I B

Deep venous thrombosis



Always Do

Treatment

Drug Therapies

建議/證據
強度 效能測量

Treat patients with an objectively confirmed DVT with subcutaneous low-molecular-weight heparin, IV unfractionated heparin (UFH), subcutaneous UFH, or subcutaneous fondaparinux in addition to a vitamin K antagonist for at least 5 days and until the INR is 2 or above for 24 hours [1].

I B

Initiate a vitamin K antagonist together with low molecular weight heparin, unfractionated heparin, or fondaparinux on the first treatment day in patients with acute DVT [1].

I B

Maintain a target INR of 2.5 (range 2 to 3) for all treatment durations when treating with a vitamin K antagonist [1].

I B

Venous thromboembolism (VTE) prophylaxis is recommended for patients who are admitted or transferred to ICU care unless there is a documented reason for not initiating VTE prophylaxis. Initiation of the appropriate therapy should occur on the first or second day of ICU care. For postoperative patients, therapy should be initiated on the day of surgery or on the day following for patients whose ICU care started one day prior to surgery or on the day of surgery (Joint Commission National Hospital Quality Measure VTE-2) [2].

I C

Joint
Commission,
CMS

Treat pregnant women with acute VTE with adjusted-dose subcutaneous low molecular weight heparin



DEFINITIONS

Strength of Evidence

A**Category A**

Category A evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.

B**Category B**

Category B evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).

C**Category C**

Category C evidence is based on data derived from: Expert opinion or consensus, case reports or case series.

PRINT  CLOSE **ALWAYS DO**

Diagnosis
Treatment
Disposition

NEVER DO

Treatment

PERFORMANCE MEASURE**RELATED INFORMATION**

Conditions
Tests & Procedures

REFERENCES

From Drug to Alternative Medicine

▼ Alternative Medicine (6)

效能比較(5)

- BASIL
- CHONDROITIN
- GLUCOSAMINE
- GUGGUL
- LYSINE

藥... 六五九四/41

OVERVIEW

DOSING INFORMATION

DOSAGE FORMS
ADULT DOSAGE

PHARMACOKINETICS

ONSET AND DURATION
DRUG CONCENTRATION LEVELS
ADME

CAUTIONS

CONTRAINDICATIONS
PRECAUTIONS
ADVERSE REACTIONS
TERATOGENICITY/EFFECTS IN PREGNANCY
DRUG INTERACTIONS

CLINICAL APPLICATIONS

MONITORING PARAMETERS
PLACE IN THERAPY
MECHANISM OF ACTION/PHARMACOLOGY
THERAPEUTIC USES
COMPARATIVE EFFICACY

REFERENCES

AUTHOR INFORMATION

GLUCOSAMINE

AltMedDex® Evaluations ⓘ

OTHER SOURCES ▶

CLINICAL APPLICATIONS

⊕ Expand All | ⊖ Collapse All | ⬆ Top of Page

▶ THERAPEUTIC USES

▼ COMPARATIVE EFFICACY

IBUPROFEN

1) SUMMARY:

a) Glucosamine is at least as effective as ibuprofen in the treatment of osteoarthritis, including osteoarthritis in the temporomandibular joint (TMJ). Glucosamine may demonstrate a slower onset of action.

2) OSTEOARTHRITIS:

a) Oral glucosamine sulfate was reported to be at least as effective as oral ibuprofen after eight weeks of treatment in one study involving 40 patients with osteoarthritis of the knee. Treatment with glucosamine sulphate 1500 milligrams or ibuprofen 1200 milligrams daily in three divided doses was assigned in a randomized and double-blind fashion. Articular pain, swelling, and general symptoms were evaluated at regular intervals. At the end of the trial, the examining physician gave an opinion of overall efficacy of treatment as good, fair, or insufficient. Pain scores decreased significantly in both groups but the onset of action was more rapid with ibuprofen, with maximum effectiveness reached after 2 weeks, whereas glucosamine was associated with a gradual, progressive improvement throughout the trial. At week 8, a good response was observed in 44% and 15% of patients receiving glucosamine and ibuprofen, respectively ($p=0.04$ for differences between treatments) (Vaz, 1982).

b) In a randomized, double-blind, parallel-group study, glucosamine 500 milligrams (mg) orally three times daily was as effective as ibuprofen 400 mg three times daily for four weeks in the treatment of 200 inpatients with osteoarthritis (OA) of the knee (Mueller-Fassbender et al, 1994). Enrollment criteria included a Lequesne index score of seven or greater, presence of OA for at least three months, and lack of concomitant OA therapy. Treatment success, defined as a decrease in Lequesne index score of at least 2 points (if baseline was greater than 12) or 1 point (if baseline was 12 or less) and a clinician rating of at least good, occurred in 48% of glucosamine patients and 52% of ibuprofen patients by study end (no significant difference). The average Lequesne score for both groups decreased from approximately 16 to 9.6 after four weeks. Therapeutic

CareNotes® in 15 Languages: Learn More

Search Path :
Keyword Search
Editorial Update

Keyword Search

SEARCH

Search:



Keyword Search | Hot Lists | Care and Condition Titles | Drug Titles | Lab Titles | Print List | Conversion Calculator

 [Print this page](#)

CareNotes® in 15 Languages: [Learn More](#)

Search Path : [Drug Titles](#) >

Search Results

Your Search: Acetaminophen/Codeine (Oral) (Tablet, Capsule, Liquid)

[Print Now](#) OR [Print Later](#)

Acetaminophen/Codeine (Oral) (Tablet, Capsule, Liquid)

DrugNote	☐ English ☐ Spanish ☐ Arabic ☐ Chinese (Simplified) ☐ Chinese (Traditional) ☐ French (Canadian) ☐ German ☐ Italian ☐ Japanese ☐ Korean ☐ Polish ☐ Portuguese (Brazilian) ☐ Russian ☐ Turkish ☐ Vietnamese
----------	---

View: Chinese (Traditional)

Print Now

OR

Print Later

Acetaminophen/Codeine (Oral) (Tablet, Capsule, Liquid) - DrugNote

乙醯胺酚/可待因 (Acetaminophen/Codeine) (口服)

乙醯胺酚 (a-seet-a-MIN-oh-fen), 磷酸可待因 (KOE-deen FOS-fate)

用於治療中度至中重度疼痛。本藥含麻醉性止痛劑。

品牌名稱： Tylenol w/Codeine #3, Tylenol w/Codeine #4, Capital w/Codeine, Tylenol w/Codeine No 4, Tylenol w/Codeine, Vopac
這種藥物可能有其他品牌名稱。

下列狀況不宜使用此藥物：

如果您對乙醯胺酚或可待因，或其他麻醉藥 (例如 Percocet®、Percodan®, Darvon®, Vicodin®) 有過敏反應，請勿服用此藥。

藥物使用方法：

錠劑, 膠囊, 口服液

- 您的醫師會告訴您這種藥的服用劑量及服用次數。未經醫師指示，切勿擅自增加用藥劑量或次數。乙醯胺酚的每日 (24 小時) 安全劑量為 4 公克 (4,000 毫克) 以下。
- 如果本藥造成腸胃不適，可與食物或牛奶一起服用。
- 請使用有刻度的量匙、口服注射器或藥杯來測量**口服液**的藥量。
- 飲用大量流質飲料以預防便秘。

如果錯過服藥時間：

- 如果您錯過服藥時間或者忘記服藥，請儘快服用。如果已接近下次服藥時間，則應跳過您漏服的藥物，等下次服藥時間到了，再依正常劑量服用。
- 切勿因為之前漏服而增加服藥劑量。

服藥警告事項：

- 如果您懷有身孕或正在餵哺母乳，或患有氣喘、肝臟疾病、腎臟疾病、排尿障礙、甲狀腺機能低下症、愛迪生症、前列腺問題、胃功能失調，或有頭部受傷或腦瘤的病史，
- 此藥可能會上癮。即使您覺得藥效不佳，**也不可擅自增加劑量**。請打電話給醫師，尋求指示。
- 當您接受其他任何醫師或牙醫的診療時，請務必告訴他們□□正在服用此藥。乙醯胺酚可能會影響某些醫學檢驗的結果。
- 服用本藥可能會使您頭暈或者昏昏欲睡。應避免開車、操作機械，或從事其他需保持警覺、否則會發生危險的工作。
- 本藥可能會造成便秘。如果長期服用，更容易發生這種現象。請詢問醫師您是否還需要使用通便劑來預防及治療便秘。
- 如果餵哺母乳的母親有服用可待因，有非常低的可能性會對嬰兒產生嚴重副作用。這是因為可待因對少數女性有不同的作用，而使得她們□□母乳包含過多的藥量。如果您嬰兒是否有這些服藥過量的症狀：睡覺時間比平常長、餵奶困難、呼吸困難，或軟弱無力。如果您發現問題，請立即打電話給嬰兒的醫師。如果您臨時找不到醫師，請帶嬰兒

服用本藥可能產生的副作用：

如果出現以下副作用，請立即打電話給您的醫師：

- 過敏反應：搔癢或出尋麻疹、臉部或手部腫脹、口腔或咽喉腫脹、胸悶、呼吸困難
- 尿色變深□□糞便呈灰白色
- 極度虛弱、呼吸短淺、心跳緩慢、盜汗或皮膚濕冷
- 噁心、嘔吐、食慾不振、上腹部疼痛
- 異常出血或瘀傷

.....

[Send CareNotes® Electronically with e-Copy: Learn More](#)

Search Path : [Care and Condition Titles](#) >

Search Results

Your Search: KIDNEY TRANSPLANT

[Print Now](#)

OR

[Print Later](#)

KIDNEY TRANSPLANT

Precare

- ☐ English
- ☐ Spanish

Inpatient Care

- ☐ English
- ☐ Spanish

Discharge Care

- ☐ English
- ☐ Spanish
- ☐ Arabic

AfterCare(R) Instructions(ER/ED)

- ☐ English
- ☐ Spanish

[Print Now](#)

OR

[Print Later](#)



Location: Shou Ray Information Service Co.

[Send CareNotes® Electronically with e-Copy: Learn More](#)

Search Path : [Care and Condition Titles](#) > [Search Results](#) >

KIDNEY TRANSPLANT

View:

- 上一頁(B)
- 下一頁(F)
- 重新載入(L)
- 另存新檔(A)...
- 列印(R)...
- 翻譯成中文 (繁體中文)(T)
- 檢視網頁原始碼(V)
- 檢視網頁資訊(I)
- 檢查元素(N)


OR

KIDNEY TRANSPLANT - Precare

Kidney Transplant

WHAT YOU SHOULD KNOW:


- Kidney transplant is surgery to replace a damaged kidney with a new kidney from a donor (another person). The kidneys are two bean-shaped organs found under the ribs on each side of the upper abdomen (stomach). The kidneys remove wastes and other unwanted chemicals from the body. These wastes are flushed from the body as urine. When the kidneys are badly damaged, these wastes build-up in the body and cause harm. This may cause seizures (convulsions), trouble breathing, increased blood pressure, body swelling, confusion, fainting, or even death. A new kidney may be needed to replace the damaged kidney to keep the body working.



Kidney Transplant

WHAT YOU SHOULD KNOW:

- Kidney transplant is surgery to replace a damaged kidney with a new kidney from a donor (another person). The kidneys are two bean-shaped organs found under the ribs on each side of the upper abdomen (stomach). The kidneys remove wastes and other unwanted chemicals from the body. These wastes are flushed from the body as urine. When the kidneys are badly damaged, these wastes build-up in the body and cause harm. This may cause seizures (convulsions), trouble breathing, increased blood pressure, body swelling, confusion, fainting, or even death. A new kidney may be needed to replace the damaged kidney to keep the body working.



此網頁內容已由 [英文](#) 翻譯成 [中文 \(繁體中文\)](#) [顯示原文](#)

選項 ▾

查看：[英語](#) ▾

[Print Now](#)

或


[Print Later](#)

腎移植 - Precare

腎移植

你應該知道：

- 腎移植手術，更換一個新的腎臟受損的腎臟從捐贈者（另一人）。腎臟是兩個豆狀上腹（胃）的每一側的肋骨下發現的機關。腎臟清除體內的廢物和其他有害化學物質。這些廢物從身體作為尿被刷新。當腎臟受損嚴重，這些廢物積聚在身體造成傷害。這可能會導致癲癇發作（抽搐），呼吸困難，血壓升高，全身浮腫，神誌不清，昏厥，甚至死亡。一個新的腎臟可能需要更換受損的腎臟，以保持身體的工作。




THE MAIN SEARCH FIELD



Starting a New Search

Any time you wish to search for something else, enter the new search term(s) or phrase in the search box, located at the top of every page.



Search Examples

To view a list of search examples, click the Example Searches link located near the top of every page



The smarter search functionality allows searches to be conducted by single and multiple terms

ERYTHROMYCIN

[e-rith-roe-MYE-sin]



不同檢索方式所導出的結果

- 單一的藥物名稱或是疾病名稱等
 - 360圖示面板
- 搭配檢索術語詞
 - 直接導入文件
 - 檢索結果清單



工具: 藥物相互作用 | Trissel's™2 IV 相容性 | **藥物鑒定** | Tox 和藥物產品查找 | 藥物比較 | RED BOOK Online® | 計算器 | 處方集 | CareNotes® | NeoFax® Pediatrics

Erythromycin

搜索

範例搜尋



360° 檢視儀錶板

MICROMEDEX® 2.0 | 移動

我的訂閱 | MICROMEDEX 開道 | 登出 | 說明

工具: 藥物相互作用 | Trissel's™2 IV 相容性 | 藥物鑒定 | Tox 和藥物產品查找 | 藥物比較 | RED BOOK Online® | 計算器 | 處方集 | CareNotes® | NeoFax® / Pediatrics

輸入一个或多个搜索条件

搜索

範例搜尋

可用途徑 ▼

Erythromycin

Erythromycin Ethylsuccinate

Erythromycin Lactobionate

Erythromycin Stearate

Ophthalmic, Oral, Topical

Oral

Intravenous

Oral

Erythromycin

Ophthalmic, Oral, Topical

360° 檢視儀錶板 | 跳轉到 981 其他搜尋結果

利用不同標籤區分同成分藥品的不同鹽類或不同劑型

MICROMEDEX 藥物綜述資訊

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA-Labeled Indications
- Non-FDA Labeled Indications
- Contraindications
- Precautions
- Pregnancy Category
- Breast Feeding
- Drug Interactions (single)
- Adverse Effects - Common
- Adverse Effects - Serious
- Drug Images (US)
- US Trade Names
- Class
- Regulatory Status
- Generic Availability
- Mechanism of Action/Pharmacokinetics
- Administration/Monitoring
- How Supplied
- Toxicology - Clinical Effects
- Toxicology - Treatment
- Toxicology - Range of Toxicity
- Clinical Teaching
- References

檢視綜述文件 ▶ | 檢視詳細文件 ▶

其他資訊

MARTINDALE

Erythromycin

INDEX NOMINUM

Erythromycin (Rec.INN)

IT-DIALOGO SUI FARMACI

- ERITROCINA 12 buste 500 mg
- ERITROCINA 12 cpr mast 200 mg
- ERITROCINA 12 cpr riv 600 mg
- ERITROCINA 6 buste 1 g

更多 ▶

PRODUCT LOOKUP

- Tox & Drug: Erythromycin
- Martindale: Erythromycin

藥物圖片 (US)



更多圖像 ▶

DRUG CONSULTS (38 結果)

- ACTINOMYCES ISRAELII INFECTIONS - DRUG OF CHOICE
- ACUTE OTITIS MEDIA - DRUG THERAPY
- ANTIBIOTIC PROPHYLAXIS IN BITE WOUNDS
- ANTIBIOTICS - SUBCONJUNCTIVAL USE IN INTRAOCULAR INFECTIONS

更多 ▶

COMPARATIVE EFFICACY (37 結果)

- Amoxicillin
- Amoxicillin/Clavulanic Acid
- Azelaic Acid
- Azithromycin

更多 ▶

療效比較



THOMSON REUTERS

Intermediate Results

897 results found for: "Erythromycin"

Top of Page

Tox & Drug: Erythromycin ▶

Display: **All (897)** | Drug (793) | Disease (74) | Toxicology (8) | Alternative Medicine (22)

Page 1: Results for: 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 Next 10 ▶

1. **ERYTHROMYCIN**
Drug: Detailed evidence-based information (*DRUGDEX*®)
2. **Erythromycin**
Ophthalmic, Oral, Topical
Drug: Summary topic (*DrugPoints*®) - See 360° View Dashboard ▶
3. **Erythromycin Lactobionate**
Intravenous
Drug: Summary topic (*DrugPoints*®) - See 360° View Dashboard ▶
4. **Erythromycin Ethylsuccinate**
Oral
Drug: Summary topic (*DrugPoints*®) - See 360° View Dashboard ▶
5. **Erythromycin Stearate**
Oral
Drug: Summary topic (*DrugPoints*®) - See 360° View Dashboard ▶
6. **PREVENTION AND TREATMENT OF BARTONELLA (ROCHALIMAE) INFECTION IN HIV-INFECTED PERSONS - CDC/NIH/IDSA GUIDELINES**
Drug: Evidence-based drug report (*Drug Consults*)
7. **TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA**
Drug: Evidence-based drug report (*Drug Consults*)
8. **TREATMENT OF STREPTOCOCCAL PHARYNGITIS AND PREVENTION OF RHEUMATIC FEVER - AHA GUIDELINES**
Drug: Evidence-based drug report (*Drug Consults*)
9. **CHLAMYDIAL INFECTIONS - CDC GUIDELINES**
Drug: Evidence-based drug report (*Drug Consults*)
10. **CHLAMYDIAL INFECTIONS AMONG INFANTS- CDC GUIDELINES**
Drug: Evidence-based drug report (*Drug Consults*)

10 results per page listed in
of order clinical relevance

Page 1: Results for: 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 Next 10 ▶

Trusted sites

100%



Drug Summary Information

Erythromycin

Ophthalmic, Oral, Topical

360° View Dashboard | [Jump to 897 other search results](#)

MICROMEDEX DRUG SUMMARY INFORMATION

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA-Labeled Indications
- Non-FDA Labeled Indications
- Contraindications
- Precautions
- Pregnancy Category
- Breast Feeding
- Drug Interactions (single)
- Adverse Effects - Common
- Adverse Effects - Serious
- Drug Images
- US Trade Names
- Class
- Regulatory Status
- Generic Availability
- Mechanism of Action/Pharmacokinetics
- Administration/Monitoring
- How Supplied
- Clinical Effects
- Treatment
- Range of Toxicity
- Clinical Teaching
- References

[View summary document ▶](#) | [View detailed document ▶](#)

DRUG TOOLS

- Side by side comparison of Erythromycin with...

Drug Summary Information shows the various categories that can easily be identified by their titles.

Clicking directly on those titles will lead the user to the summary document.

Erythromycin was also found in...

▶ **Toxicology and Exposure Information (7)**

▶ **Disease Information (26)**

http://www.thomsonhc.com/micromedex2/librarian/ND_T/evidenceexpert/ND_PR/evidenceexpert/CS/CCD2A9/ND_AppProduct/evidenceexpert/DUP

Trusted sites

125%



工具:	藥物 相互作用	Trissel's™ IV 相容性	藥物 鑒定	Tox 和藥物 產品查找	藥物 比較	RED BOOK Online®	計算器	處方集	CareNotes®	NeoFax® / Pediatrics
-----	------------	----------------------	----------	-----------------	----------	---------------------	-----	-----	------------	-------------------------

dosing for ERYTHROMYCIN

SEARCH

範例搜尋



直接導入文件

MICROMEDEX® 2.0 | 移動

[我的訂閱](#) | [MICROMEDEX 開道](#) | [登出](#) | [說明](#)

工具:	藥物 相互作用	Trissel's™ IV 相容性	藥物 鑒定	Tox 和藥物 產品查找	藥物 比較	RED BOOK Online®	計算器	處方集	CareNotes®	NeoFax® / Pediatrics
-----	------------	----------------------	----------	-----------------	----------	---------------------	-----	-----	------------	-------------------------

輸入一个或多个搜索条件

SEARCH

範例搜尋

DOSING & INDICATIONS

 [顯示整個文件](#) |  [列印](#)

Adult Dosing
Pediatric Dosing
Dose Adjustments
FDA-Labeled Indications
Non-FDA Labeled Indications

Erythromycin

DrugPoint® 綜述

 [其他來源](#)

 [全部展開](#) |  [全部折疊](#) |  [頁首](#)

CONTRAINDICATIONS/WARNINGS

Contraindications
Precautions
Pregnancy Category
Breast Feeding

DRUG INTERACTIONS (SINGLE)

ADVERSE EFFECTS

Common
Serious

NAME INFO

Drug Images (US)
US Trade Names
Class

DOSING & INDICATIONS

- ▶ **Adult Dosing**
- ▶ **Pediatric Dosing**
- ▶ **Dose Adjustments**
- ▶ **FDA-Labeled Indications**
- ▶ **Non-FDA Labeled Indications**

工具:	藥物 相互作用	Trissel's™ IV 相容性	藥物 鑒定	Tox 和藥物 產品查找	藥物 比較	RED BOOK Online®	計算器	處方集	CareNotes®	NeoFax® / Pediatrics
-----	------------	----------------------	----------	-----------------	----------	---------------------	-----	-----	------------	-------------------------

treatment for headache

搜索

範例搜尋



3584 找到以下項的結果: "treatment for headache"

顯示: [全部 \(3584\)](#) | [藥物 \(3126\)](#) | [疾病 \(292\)](#) | [替代藥物 \(166\)](#)

頁面 1: 以下項的結果: 1-10

[1](#) | [2](#) | [3](#) | [4](#) | [5](#) | [6](#) | [7](#) | [8](#) | [9](#) | [10](#) 後面 10 個 ▶

1. [Headache](#)

Disease: [Summary topic \(Clinical Points®\)](#) - 請參見 360° 檢視儀錶板 ▶

Document section:

▀ [Treatment](#) ▶

2. [Headache](#)

Disease: [Detailed evidence-based information \(DISEASEDEX™\)](#) - 請參見 360° 檢視儀錶板 ▶

Document section:

▀ [Treatment](#) ▶

3. [Headache](#)

Disease: [List of essential care interventions \(Clinical Checklist®\)](#)

4. [Cluster headache](#)

Disease: [Summary topic \(Clinical Points®\)](#) - 請參見 360° 檢視儀錶板 ▶

Document section:

▀ [Treatment](#) ▶

...

輸入一个或多个搜索条件

搜索

範例搜尋

DEFINITION

MEDICAL HISTORY

FINDINGS

DIFFERENTIAL DIAGNOSIS

TESTING

TREATMENT

Drug Therapy

Procedural Therapy

Non-Procedural Therapy

REFERENCE

Headache

 顯示整個文件 |  列印DISEASEDEX™ 急診綜述 

其他來源 ▶

檢視相關文件:  臨床檢查表單 全部展開 |  全部折疊 |  頁首

TREATMENT

▼ Drug Therapy

檢視 DISEASEDEX™ 中的詳細資訊 ▶

Headache

ACETAMINOPHEN (Related toxicological information in **ACETAMINOPHEN-ACUTE**, **ACETAMINOPHEN-REPEATED SUPRATHERAPEUTIC**)

Adults: 650 to 1000 mg orally every 4 to 6 hours as needed (maximum 4 g/day) [19]

Pediatrics: 10 to 15 mg/kg orally or rectally every 4 to 6 hours as needed (maximum 5 doses or 4 g/day) [20][19]

Neonates: 10 to 15 mg/kg orally or rectally every 6 to 8 hours as needed

IBUPROFEN (Related toxicological information in **IBUPROFEN**)

特定檢索術語詞的運用

Chemotherapy – For acronyms and dosing

beta-blocker – Comparative dosing table

Corticosteroid - Comparative dosing table

table – Alphabetical list of Comparative dosing tables



1083 藥物 找到以下項的結果: "Chemotherapy"

顯示: 全部 (2540) | **藥物 (1083)** | eMC SmPC (UK) (365) | 疾病 (167) | 毒理學 (603) | 實驗室 (18) | 替代藥物 (137) | 生殖風險 (173)

頁面 1: 以下項的結果: 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. CHEMOTHERAPY ACRONYMS AND DOSING

Drug: Evidence-based drug report (Drug Consults)

CHEMOTHERAPY ACRONYMS AND DOSING PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND Use...

2. CHEMOTHERAPY DOSING IN OBESE ADULTS

Drug: Evidence-based drug report (Drug Consults)

CHEMOTHERAPY DOSING IN OBESE ADULTS PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND...

3. CHEMOTHERAPY AND RADIOTHERAPY PROTECTANTS - ASCO CLINICAL PRACTICE GUIDELINES

Drug: Evidence-based drug report (Drug Consults)

CHEMOTHERAPY AND RADIOTHERAPY PROTECTANTS - ASCO CLINICAL PRACTICE GUIDELINES PATIENT DATA/BACKGROUND...

CHEMOTHERAPY ACRONYMS AND DOSING

藥物諮詢 

- Mitoxantrone 10 mg/m(2) IV, day 1
- Vincristine 1.4 mg/m(2) (max 2 mg) IV, day 1
- Prednisone 50 mg/m(2) ORALLY, days 1 to 5
- Repeat cycle every 21 days

- COMLA - Used for lymphoma, non-Hodgkin's
 - Cyclophosphamide 1500 mg/m(2) IV, day 1
 - Vincristine 1.4 mg/m(2) (max 2 mg) IV, days 1, 8, and 15
 - Methotrexate 120 mg/m(2) IV, days 22, 29, 36, 43, 50, 57, 64, and 71
 - Leucovorin 25 mg/m(2) ORALLY, every 6 hours for 4 doses beginning 24 hours after each methotrexate dose
 - Cytarabine 300 mg/m(2) IV, days 22, 29, 36, 43, 50, 57, 64, and 71
 - Repeat cycle every 12 weeks

- **COP** - Used for lymphoma, non-Hodgkin's
 - Cyclophosphamide 800 mg/m(2) IV, day 1
 - Vincristine 1.4 mg/m(2) (max 2 mg) IV, day 1
 - Prednisone 60 mg/m(2) ORALLY, days 1 to 5
 - Repeat cycle every 14 days

- CP - Used for ovarian cancer, epithelial
 - Cyclophosphamide 750 mg/m(2) IV, day 1
 - Cisplatin 75 mg/m(2) IV, day 1
 - Repeat cycle every 21 days

- CT - Used for ovarian cancer, epithelial

Ctrl+F, 可速查閱



588 藥物 找到以下項的結果: "beta-blocker"

顯示: 全部 (995) | **藥物 (588)** | eMC SmPC (UK) (196) | 疾病 (85) | 毒理學 (85) | 實驗室 (1) | 替代藥物 (14) | 生殖風險 (26)

頁面 1: 以下項的結果: 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. BETA BLOCKER EXACERBATION OF PSORIASIS

Drug: Evidence-based drug report (*Drug Consults*)

...by a temporal relationship with **beta-blocker** drug therapy [1] [3] [4] [5] [6] [7] . Beta adrenergic...

2. BETA BLOCKER USE IN ARRHYTHMIAS

Drug: Evidence-based drug report (*Drug Consults*)

5] [6] [7] [8] . Concomitant **beta-blocker** therapy during decompensated congestive heart failure may be associated with...

3. BETA BLOCKER USE IN HYPERTENSION

Drug: Evidence-based drug report (*Drug Consults*)

...beta blocker treatment. Significantly more **beta-blocker**-treated patients were likely to discontinue treatment compared with patients...

4. BETA BLOCKER USE IN ANGINA PECTORIS

Drug: Evidence-based drug report (*Drug Consults*)

5. BETA BLOCKER USE IN POSTMYOCARDIAL INFARCTION

Drug: Evidence-based drug report (*Drug Consults*)

...in patients entered in the **Beta-Blocker** Heart Attack Trial with their first myocardial infarction and persistent...



2416 藥物 找到以下項的結果："Corticosteroid"

顯示： 全部 (8373) | **藥物 (2416)** | eMC SmPC (UK) (1337) | 疾病 (496) | 毒理學 (3619) | 實驗室 (19) | 替代藥物 (193) | 生殖風險 (293)

頁面 1: 以下項的結果： 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. **CORTICOSTEROID (Dental route)**
Drug: Patient education handouts (*Detailed Drug Information for the Consumer™*)
...often by their doctor. Dental **corticosteroids** may be absorbed through the lining of the mouth and...
Document section:
 - Before Using This Medicine ▶
2. **CORTICOSTEROID (Ophthalmic route)**
Drug: Patient education handouts (*Detailed Drug Information for the Consumer™*)
...to the effects of ophthalmic **corticosteroids**. This may increase the chance of side effects. If this...
Document section:
 - Before Using This Medicine ▶
3. **CORTICOSTEROID (Nasal route)**
Drug: Patient education handouts (*Detailed Drug Information for the Consumer™*)
...or package ingredients carefully. Pediatric **Corticosteroids** taken by mouth or injection have been shown to slow...
Document section:
 - Before Using This Medicine ▶
4. **CORTICOSTEROID (Otic route)**
Drug: Patient education handouts (*Detailed Drug Information for the Consumer™*)
...born to mothers taking otic **corticosteroid** therapy during their pregnancy should be observed for decrease in...
Document section:
 - Before Using This Medicine ▶



2416 藥物 找到以下項的結果："Corticosteroid"

顯示：[全部 \(8373\)](#) | [藥物 \(2416\)](#) | [eMC SmPC \(UK\) \(1337\)](#) | [疾病 \(496\)](#) | [毒理學 \(3619\)](#) | [實驗室 \(19\)](#) | [替代藥物 \(193\)](#) | [生殖風險 \(293\)](#)

頁面 2: 以下項的結果： 11-20

[1](#) | [2](#) | [3](#) | [4](#) | [5](#) | [6](#) | [7](#) | [8](#) | [9](#) | [10](#) 後面 10 個 ▶

11. COMPARATIVE DOSAGE TABLE - CORTICOSTEROIDS PROPERTIES AND POTENCIES

Drug: Evidence-based drug report (*Drug Consults*)

Azarnoff DL: Clinical complications of **corticosteroid** therapy. A selected review. Med Clin North Am 1973; 57...

12. REVIEW OF SYSTEMIC ADVERSE EFFECTS ASSOCIATED WITH CORTICOSTEROIDS

Drug: Evidence-based drug report (*Drug Consults*)

...interpretation of the effect of **corticosteroid** therapy on growth [1] . The ideal study to assess the...

13. Corticosteroids

Drug: International Drug Information (*Martindale*)

14. DRUG THERAPY OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS

Drug: Evidence-based drug report (*Drug Consults*)

...on acute manifestations, clinical symptoms, **corticosteroid** requirements, and chest radiograph findings. Stage I is the acute...

15. DRUG THERAPY OF TEMPORAL ARTERITIS AND POLYMYALGIA RHEUMATICA

Drug: Evidence-based drug report (*Drug Consults*)

...effect profile of long-term **corticosteroid** use can lead to problems, particularly in the patient population...

16. PARAMETHASONE

Drug: Detailed evidence-based information (*DRUGDEX®*)

...route 1 Paramethasone is a **corticosteroid** (glucocorticoid), which may be used in applications where an oral...

Document section:

▪ [Adult Dosage](#) ▶



1070 藥物 找到以下項的結果: "table"

顯示: 全部 (6506) | 藥物 (1070) | eMC SmPC (UK) (1375) | 疾病 (101) | 毒理學 (3063) | 實驗室 (7) | 替代藥物 (40) | 生殖風險 (850)

頁面 1: 以下項的結果: 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. **COMPARATIVE DOSAGE TABLE - ACE INHIBITORS**

Drug: Evidence-based drug report (*Drug Consults*)

COMPARATIVE DOSAGE **TABLE** - ACE INHIBITORS RESPONSE RESPONSE The following chart provides recommended adult...

2. **COMPARATIVE DOSAGE TABLE - BENZODIAZEPINES (SELECTED)**

Drug: Evidence-based drug report (*Drug Consults*)

COMPARATIVE DOSAGE **TABLE** - BENZODIAZEPINES (SELECTED) RESPONSE RESPONSE The following chart provides selected benzodiazepine...

3. **COMPARATIVE DOSAGE TABLE - EXPECTORANT COMBINATIONS**

Drug: Evidence-based drug report (*Drug Consults*)

COMPARATIVE DOSAGE **TABLE** - EXPECTORANT COMBINATIONS RESPONSE RESPONSE The following **table** lists representative non...

4. **COMPARATIVE DOSAGE TABLE - ANALGESIC DECONGESTANT ANTIHISTAMINE COMBINATIONS**

Drug: Evidence-based drug report (*Drug Consults*)

COMPARATIVE DOSAGE **TABLE** - ANALGESIC DECONGESTANT ANTIHISTAMINE COMBINATIONS PATIENT DATA/BACKGROUND PATIENT DATA...

5. **COMPARATIVE DOSAGE TABLE - ANGIOTENSIN II RECEPTOR ANTAGONISTS**

Drug: Evidence-based drug report (*Drug Consults*)

COMPARATIVE DOSAGE **TABLE** - ANGIOTENSIN II RECEPTOR ANTAGONISTS RESPONSE RESPONSE The following chart provides...

6. **COMPARATIVE DOSAGE TABLE - ANTIDIABETIC AGENTS (SELECTED)**

Drug: Evidence-based drug report (*Drug Consults*)

COMPARATIVE DOSAGE **TABLE** - ANTIDIABETIC AGENTS (SELECTED) RESPONSE RESPONSE The following chart provides selected...

7. **COMPARATIVE DOSAGE TABLE - BETA-ADRENERGIC BLOCKERS (SELECTED)**



特定檢索術語詞的運用

guidelines – A list of CDC guidelines.

Crushed - Get a list of tablets or capsules that should not be crushed.

management - List of managing different diseases

drug of choice - used to evaluate therapies for different indications
Antimicrobial of choice
evaluate antimicrobial therapies for different indications



1631 藥物 找到以下項的結果： "guidelines"

顯示： 全部 (8122) | 藥物 (1631) | eMC SmPC (UK) (616) | 疾病 (448) | 毒理學 (4090) | 實驗室 (35) | 替代藥物 (416) | 生殖風險 (886)

頁面 1: 以下項的結果： 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. BACTERIAL VAGINOSIS - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

BACTERIAL VAGINOSIS - CDC GUIDELINES RESPONSE RESPONSE Bacterial vaginosis (BV) is a polymicrobial clinical syndrome...

2. CHANCROID - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

CHANCROID - CDC GUIDELINES PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND DISEASES CHARACTERIZED BY GENITAL...

3. CHLAMYDIAL INFECTIONS - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

CHLAMYDIAL INFECTIONS - CDC GUIDELINES PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND CHLAMYDIAL INFECTIONS IN ADO...

4. EPIDIDYMITIS - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

EPIDIDYMITIS - CDC GUIDELINES RESPONSE RESPONSE For acute epididymitis, the most frequent causative pathogens...

5. GENITAL WARTS - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

GENITAL WARTS - CDC GUIDELINES RESPONSE RESPONSE Human papillomavirus (HPV) 6 or 11 causes 90...

6. GONOCOCCAL INFECTIONS - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

GONOCOCCAL INFECTIONS - CDC GUIDELINES PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND GONOCOCCAL INFECTIONS IN A...

7. HEPATITIS A - CDC GUIDELINES

Drug: Evidence-based drug report (*Drug Consults*)

HEPATITIS A - CDC GUIDELINES PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND HEPATITIS A IN ADO...



顯示： 全部 (976) | 藥物 (363) | eMC SmPC (UK) (236) | 疾病 (6) | 毒理學 (316) | 實驗室 (1) | 替代藥物 (47) | 生殖風險 (7)

頁面 1: 以下項的結果： 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. TABLETS/CAPSULES THAT SHOULD NOT BE CRUSHED GUIDE

Drug: Evidence-based drug report (*Drug Consults*)

CAPSULES THAT SHOULD NOT BE **CRUSHED** GUIDE RESPONSE RESPONSE A variety of oral solid dosage form

2. ENTERAL FEEDING TUBES AND MEDICATION DELIVERY

Drug: Evidence-based drug report (*Drug Consults*)

...tube, provided they are not **crushed** [4] [1] and the pellets are small enough to pass...

3. Finasteride

Oral

Drug: Summary topic (*DrugPoints®*) - 請參見 360° 檢視儀錶板 ▶

...absorption may occur; broken or **crushed** capsules should not be handled by women of childbearing potential...

Document section:

▪ Precautions ▶

4. Colestipol Hydrochloride

5157 藥物 找到以下項的結果 : "management"

顯示 : 全部 (15394) | 藥物 (5157) | eMC SmPC (UK) (1858) | 疾病 (1295) | 毒理學 (5368) | 實驗室 (209) | 替代藥物 (341) | 生殖風險 (1166)

頁面 1: 以下項的結果 : 1-10 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

- 1. LATEX ALLERGY MANAGEMENT
Drug: Evidence-based drug report (Drug Consults)
LATEX ALLERGY **MANAGEMENT** RESPONSE RESPONSE Latex is a sap derived from the Hevea...
- 2. TUMOR LYSIS SYNDROME - MANAGEMENT
Drug: Evidence-based drug report (Drug Consults)
TUMOR LYSIS SYNDROME - **MANAGEMENT** PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND Tumor lysis syndrome (TLS...
- 3. GUIDELINES FOR THE PHARMACOLOGICAL MANAGEMENT OF ASTHMA
Drug: Evidence-based drug report (Drug Consults)
GUIDELINES FOR THE PHARMACOLOGICAL **MANAGEMENT** OF ASTHMA PATIENT DATA/BACKGROUND PATIENT DATA/BACKGROUND The pha...
- 4. GUIDELINES - PHARMACOLOGIC MANAGEMENT OF DIABETES MELLITUS (DM)
Drug: Evidence-based drug report (Drug Consults)
GUIDELINES - PHARMACOLOGIC **MANAGEMENT** OF DIABETES MELLITUS (DM) RESPONSE RESPONSE CLASSIFICATION FOR DIABETES ME...
- 5. MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN ADULTS
Drug: Evidence-based drug report (Drug Consults)
MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN ADULTS PATIENT DATA/BACKGROUND PATIENT...
- 6. MANAGEMENT OF HELICOBACTER PYLORI INFECTION - ACG GUIDELINES
Drug: Evidence-based drug report (Drug Consults)
MANAGEMENT OF HELICOBACTER PYLORI INFECTION - ACG GUIDELINES RESPONSE RESPONSE The American...
- 7. -----

1295 疾病 找到以下項的結果："management"

顯示： 全部 (15394) | 藥物 (5157) | eMC SmPC (UK) (1858) | **疾病 (1295)** | 毒理學 (5368) | 實驗室 (209) | 替代藥物 (341) | 生殖風險 (1166)

頁面 1: 以下項的結果： 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. Transplant donor management

Disease: Summary topic (Clinical Points®) - 請參見 360° 檢視儀錶板 ▶

...to ensure organ viability [8] . **Management** of organ and tissue transplant donors Family counseling: A multidisciplinary...

Document section:

▪ Procedural Therapy ▶

2. Wound care management

Disease: Summary topic (Clinical Points®) - 請參見 360° 檢視儀錶板 ▶

...medical care [28] . Wound care **management** [29] [3] [30] [31] [32] Exploration of wound of skin...

Document section:

▪ Procedural Therapy ▶

3. Cancer pain management

Disease: Summary topic (Clinical Points®) - 請參見 360° 檢視儀錶板 ▶

4. Cancer pain management

Disease: Detailed evidence-based information (DISEASEDEX™) - 請參見 360° 檢視儀錶板 ▶

...emergency [1] [7] . Basing pain **management** only on pain intensity is inadequate and potentially unsafe [2...

Document section:

▪ Clinical Evaluation ▶

5. Wound care management

Disease: Detailed evidence-based information (DISEASEDEX™) - 請參見 360° 檢視儀錶板 ▶

...anesthesia for adequate evaluation and **management** . Wound exploration is indicated to rule out neurovascular, tendon, or...

Document section:



THOMSON REUTERS

顯示: 全部 (1076) | 藥物 (696) | eMC SmPC (UK) (26) | 疾病 (125) | 毒理學 (190) | 替代藥物 (30) | 生殖風險 (9)

頁面 1: 以下項的結果: 1-10

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 後面 10 個 ▶

1. ACINETOBACTER INFECTIONS - DRUG OF CHOICE

Drug: Evidence-based drug report (*Drug Consults*)

ACINETOBACTER INFECTIONS - **DRUG OF CHOICE** RESPONSE RESPONSE ACINETOBACTER* INFECTIONS *Resistance may be a problem; sus

2. AEROMONAS INFECTIONS - DRUG OF CHOICE

Drug: Evidence-based drug report (*Drug Consults*)

AEROMONAS INFECTIONS - **DRUG OF CHOICE** RESPONSE RESPONSE AEROMONAS* INFECTIONS *Resistance may be a problem; susceptibili

3. BACTEROIDES INFECTIONS - DRUG OF CHOICE

Drug: Evidence-based drug report (*Drug Consults*)

BACTEROIDES INFECTIONS - **DRUG OF CHOICE** RESPONSE RESPONSE BACTEROIDES* INFECTIONS *Resistance may be a problem; suscepti

4. BARTONELLA INFECTIONS - DRUG OF CHOICE

Drug: Evidence-based drug report (*Drug Consults*)

BARTONELLA INFECTIONS - **DRUG OF CHOICE** RESPONSE RESPONSE BARTONELLA INFECTIONS ----- A

5. BRUCELLA INFECTIONS - DRUG OF CHOICE

Drug: Evidence-based drug report (*Drug Consults*)

BRUCELLA INFECTIONS - **DRUG OF CHOICE** RESPONSE RESPONSE BRUCELLA INFECTIONS * *Resistance may be a problem; susceptibility...

6. ENTEROBACTER INFECTIONS - DRUG OF CHOICE

Drug: Evidence-based drug report (*Drug Consults*)

ENTEROBACTER INFECTIONS - **DRUG OF CHOICE** RESPONSE RESPONSE ENTEROBACTER* INFECTIONS *Resistance may be a problem; sus

RED BOOK Online®



RED BOOK Online®

- 找尋最新藥物價格與處方箋包裝資訊
- 每日更新最新資訊
- 通知最新價格資訊
- 提供品牌藥物和一般性藥物前後一致, 無任何偏見的平均批發價(Average Wholesale Price, AWP)資訊



從產品名查找

西藥 / 心血管疾病用藥 / 立普妥

產品分類：	降血脂劑
英文品名：	Lipitor
中文品名：	立普妥
成份名：	ATORVASTATIN (CALCIUM TRIHYDRATE)
劑 型：	膜衣錠
劑量單位：	10mg/錠劑，20mg/錠劑，40mg/錠劑
規格包裝：	10mg-28錠/盒，20mg-28錠/盒，40mg-28錠/盒
適應症／ 用 途：	高膽固醇血症, 高三酸甘油酯血症。 對於臨床上沒有冠心病的第二型糖尿病患者，但是至少有任一其他冠心病危險因子,包括高血壓、視網膜病變、白蛋白尿、或吸菸，Lipitor 適用於：降低心肌梗塞的風險、降低中風的風險。 降低冠心病高危險群的心血管事件發生率 對於臨床上沒有冠心病的高血壓患者，但是至少有三個其他冠心病危險因子,包括第二型糖尿病、年紀大於等於55歲、微白蛋白尿或蛋白尿、吸煙或第一等親在55歲 (男性) 或 60歲 (女性) 前曾發生冠心病事件，Lipitor 適用於：降低心肌梗塞的風險、降低中風的風險、降低血管再造術與心絞痛的風險。



RED BOOK Online® 搜尋

按照產品名稱或製造商搜尋處方或處方藥、保健品、散裝化學品、醫療設備或用品。按照產品的特定活性成分或按照特定代碼（例如 NDC、UPC 或 HPI）。

我想按以下項搜尋...

- ☒ 產品名稱
- ☐ 活性成分
- ☐ NDC/HRI/UPC
- ☐ 製造商名稱

我想按以下項篩選...

狀態：

- ☒ 作用中
- ☐ 已停用
- ☐ 全部

重新包裝商：

- ☐ 包括重新包裝商
- ☒ 排除重新包裝商

輸入搜尋詞：

LIPITOR

提交

LIPITOR



顯示有關以下項的結果 "產品名稱: LIPITOR" 應用的篩選: Status - Active; Repackagers - Exclude

結果 1 - 14 / 14

Page 1 of 1 Go | 前面 | 後面

Details	價格變更	新包裝	產品名稱 ▾	活性成分	製造商/ 分銷商	重新包裝	學名藥	橙皮書代碼	代碼類型	識別碼	劑型	強度	用法	包裝大小	單位劑量	WAC 組合價格	AWP 組合價格	AWP 單價
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-23	TAB	10 mg	ORAL	90s ea	N	337.30	404.76	4.49733
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0156-23	TAB	20 mg	ORAL	90s ea	N	481.14	577.37	6.41522
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-73	TAB	40 mg	ORAL	500s ea	N	2672.97	3207.56	6.41512
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-23	TAB	40 mg	ORAL	90s ea	N	481.14	577.37	6.41522
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-40	TAB	40 mg	ORAL	100s ea	Y	561.34	673.61	6.73610
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-88	TAB	40 mg	ORAL	2500s ea	N	13364.87	16037.84	6.41514
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0158-23	TAB	80 mg	ORAL	90s ea	N	481.14	577.37	6.41522
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-34	TAB	10 mg	ORAL	5000s ea	N	18739.29	22487.15	4.49743
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0156-94	TAB	20 mg	ORAL	5000s ea	N	26729.75	32075.70	6.41514
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0156-40	TAB	20 mg	ORAL	100s ea	Y	561.34	673.61	6.73610

顯示有關以下項的結果 "產品名稱：LIPITOR" 應用的篩選：Status - Active; Repackagers - Exclude

結果 1-14 / 14

Page 1 of 1 Go | ◀ 前面 | 後面 ▶

Details	價格變更	新包裝	產品名稱 ▼	活性成分	製造商/ 分銷商	重新包裝	學名藥	橙皮書代碼	代碼類型	識別碼	劑型	強度	用法	包裝大小	單位測量	WAC 組合價格	AWP 組合價格	AWP 單價
			LIPITOR	atorvastatin calcium	選擇此項目以查看具有相同活性成分、劑型、強度和用法的所有其他藥物的表單。						TAB	10 mg	ORAL	90s ea	N	337.30	404.76	4.49733
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0156-23	TAB	20 mg	ORAL	90s ea	N	481.14	577.37	6.41522
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-73	TAB	40 mg	ORAL	500s ea	N	2672.97	3207.56	6.41512
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-23	TAB	40 mg	ORAL	90s ea	N	481.14	577.37	6.41522
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-40	TAB	40 mg	ORAL	100s ea	Y	561.34	673.61	6.73610
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0157-88	TAB	40 mg	ORAL	2500s ea	N	13364.87	16037.84	6.41514
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0158-23	TAB	80 mg	ORAL	90s ea	N	481.14	577.37	6.41522
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-34	TAB	10 mg	ORAL	5000s ea	N	18739.29	22487.15	4.49743

RED BOOK Online® 搜尋結果

修改搜尋

- 導出為 -

顯示有關以下項的結果 "產品名稱：LIPITOR"

應用的篩選：Status - Active; Repackagers - Exclude

結果 1 - 14 / 14

Page 1 of 1 Go | 前

Details	價格變更	新包裝	產品名稱 ▾	活性成分	製造商/分銷商	重新包裝	學名	橙皮素代碼	代碼類型	識別碼	劑型	強度	用法	包裝大小	單位劑量	WAC 組合價格	AWP 組合價格
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.						ORAL	90s ea	N	337.30		404.7	
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.						ORAL	90s ea	N	481.14		577.3	
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.						ORAL	500s ea	N	2672.97		3207.9	
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.						ORAL	90s ea	N	481.14		577.3	
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.						ORAL	100s ea	Y	561.34		673.0	
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.						ORAL	2500s ea	N	13364.87		16037.8	
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0158-23	TAB	80 mg	ORAL	90s ea	N	481.14	577.3
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-34	TAB	10 mg	ORAL	5000s ea	N	18739.29	22487.7
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0156-94	TAB	20 mg	ORAL	5000s ea	N	26729.75	32075.1
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0156-40	TAB	20 mg	ORAL	100s ea	Y	561.34	673.0
☐			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0158-73	TAB	80 mg	ORAL	500s	N	2672.97	3207.9

查找類似的產品

您將提交針對匹配這些條件的所有項目的搜尋。

活性成分：

劑型：

強度：

用法：

狀態：

重新包裝商：

atorvastatin calcium

TAB

10 mg

ORAL

Active

Exclude

提交✔

關閉✕

查找類似的產品

您將提交針對匹配這些條件的所有項目的搜尋。

活性成分： atorvastatin calcium
 劑型： TAB
 強度： 10 mg
 用法： ORAL
 狀態： Active
 重新包裝商： Exclude

提交 ✓ 關閉 ✕



顯示有關以下項的結果 "活性成分: atorvastatin calcium 劑型: TAB 強度: 10 mg 用法: ORAL" 應用的篩選: Status - Active; Repackagers - Exclude

結果 1 - 14 / 14

Page 1 of 1 Go | [前面](#) | [後面](#)

Details	價格變更	新包裝	產品名稱	製造商/分銷商	重新包裝	學名藥	複皮書代碼	代碼類型	識別碼	包裝大小	WAC 單價	AWP 單價
☐			ATORVASTATIN CALCIUM	APOTEX CORP.	N	Y	AB	NDC	60505-2578-09	90s ea	1.02000	4.04756
☐			ATORVASTATIN CALCIUM	MAJOR PHARMACEUTICALS	N	Y	AB	NDC	00904-6290-61	100s ea	0.30970	3.55040
☐		★	ATORVASTATIN CALCIUM	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0409-01	ea	--	--
☐	\$	★	ATORVASTATIN CALCIUM	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0409-20	100s ea	0.30930	0.36790
☐			ATORVASTATIN CALCIUM	MYLAN PHARMACEUTICALS, INC.	N	Y	AB	NDC	00378-2015-77	90s ea	--	4.04311
☐			ATORVASTATIN CALCIUM	MYLAN PHARMACEUTICALS, INC.	N	Y	AB	NDC	00378-2015-05	500s ea	--	4.04310
☐			ATORVASTATIN CALCIUM	RANBAXY PHARMACEUTICALS, INC.	N	Y	--	NDC	63304-0827-90	90s ea	0.42833	3.85067
☐			ATORVASTATIN CALCIUM	RANBAXY PHARMACEUTICALS, INC.	N	Y	--	NDC	63304-0827-05	500s ea	0.56218	4.04320
☐			ATORVASTATIN CALCIUM	SANDOZ	N	Y	AB	NDC	00781-5381-92	90s ea	0.51400	3.85489
☐			ATORVASTATIN CALCIUM	WATSON PHARMA, INC.	N	Y	--	NDC	00591-3774-19	90s ea	0.51400	0.61678
☐			ATORVASTATIN CALCIUM	WATSON PHARMA, INC.	N	Y	--	NDC	00591-3774-10	1000s ea	0.51401	0.61681
☐			LIPITOR	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-40	100s ea	3.93500	4.72200
☐			LIPITOR	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-23	90s ea	3.74778	4.49733
☐			LIPITOR	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-34	5000s ea	3.74786	4.49743

查詢特定公司銷售藥物及價格

MICROMEDEX® 2.0 | 移動

我的訂閱

工具: 藥物
相互作用

Trissel's™2
IV 相容性

藥物
鑒定

Tox 和藥物
產品查找

藥物
比較

RED BOOK
Online®

計算器

處方集

CareNotes®

NeoFax® /
Pediatrics

輸入一个或多个搜索条件

搜索

範例搜尋

RED BOOK Online® 搜尋

按照產品名稱或製造商搜尋處方或處方藥、保健品、散裝化學品、醫療設備或用品。按照產品的特定活性成分或按照特定代碼（例如 NDC、UPC 或 HRI）進行搜尋。

我想按以下項搜尋...

- ☐ 產品名稱
- ☐ 活性成分
- ☐ NDC/HRI/UPC
- ☒ 製造商名稱

輸入搜尋詞:

Takeda

提交

TAKEDA PHARMACEUTICALS AMERICA, INC.



從以下項的表單中選擇： 18 為以下項找到的產品："製造商：TAKEDA PHARMACEUTICALS AMERICA, INC."

跳轉到：頁首 | 0-9 | [A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

A

ACTOPLUS MET

ACTOPLUS MET XR

ACTOS

AMITIZA

D

DEXILANT

DUETACT

工具: 藥物相互作用 | Trissel's™2 IV 相容性 | 藥物鑒定 | Tox 和藥物產品查找 | 藥物比較 | RED BOOK Online® | 計算器 | 處方集 | CareNotes® | NeoFax® / Pediatrics

搜索

範例搜尋

RED BOOK Online® 搜尋結果

修改搜尋

- 導出為 - ▾

| 列印

顯示有關以下項的結果 "製造商: TAKEDA PHARMACEUTICALS AMERICA, INC. 產品名稱: AMITIZA"

結果 1-3 / 3

Page 1 of 1 Go | ◀前面 | 後面▶

Details	價格變更	新包裝	產品名稱 ▾	活性成分	製造商/分銷商	重新包裝	學名藥	橙皮書代碼	代碼類型	識別碼	劑型	強度	用法	包裝大小	單位劑量	WAC 組合價格	AWP 組合價格	AWP 單價
			AMITIZA 已停用	lubiprostone	TAKEDA PHARMACEUTICALS AMERICA, INC.	N	N	--	NDC	64764-0240-10	SGL	24 mcg	ORAL	100s ea	N	288.42	346.10	3.46100
			AMITIZA	lubiprostone	TAKEDA PHARMACEUTICALS AMERICA, INC.	N	N	--	NDC	64764-0080-60	SGL	8 mcg	ORAL	60s ea	N	246.92	296.30	4.93833
			AMITIZA	lubiprostone	TAKEDA PHARMACEUTICALS AMERICA, INC.	N	N	--	NDC	64764-0240-60	SGL	24 mcg	ORAL	60s ea	N	246.92	296.30	4.93833



藥物
相互作用

Trissel's™ 2
IV 相容性

輸入一个

RED BOOK Online® 搜尋

顯示有關以下項的結果 "製造商":

結果 1 - 3 / 3

Details 價格變更 新包裝

AMITIZA
已停用

AMITIZA
已停用

AMITIZA

AMITIZA

RED BOOK ONLINE® 產品詳細資訊

1 of 3

產品資訊

產品名稱: AMITIZA
已停用

活性成分: lubiprostone

製造商/分銷商: TAKEDA PHARMACEUTICALS
AMERICA, INC.

劑型: CAPSULE, LIQUID FILLED

強度: 24 mcg

大小: 100s ea

給藥途徑: ORAL

橙皮書代碼: --

DEA 類別: RX

代碼: NDC

識別碼: 64764-0240-10

單位劑量: N

單一來源: Y

重新包裝商: N

學名藥: N

新增說明: (SOFT GELATIN CAPSULE)

當前定價資訊:

	包裝	單位	有效日期
AWP	346.10	3.46100	06/28/2007
WAC	288.42	2.88420	06/28/2007
DIR	--	--	--

AWP 單位定價歷史記錄:

有效日期	單位	變更百分比
06/28/2007	3.46100	9.9
12/01/2006	3.14930	8.0
03/15/2006	2.91600	0.0

J 代碼:

--
--
--

範例搜尋

導出為 - 列印

Page 1 of 1 Go | 前面 | 後面

單位 劑量	WAC 組合 價格	AWP 組合 價格	AWP 單 價
N	288.42	346.10	3.46100

N	246.92	296.30	4.93833
---	--------	--------	---------

N	246.92	296.30	4.93833
---	--------	--------	---------

主頁 | 聯絡我們 | 關於我們 | 內容更新

COPYRIGHT © 1974-2012 Thomson Reuters

列印 關閉 X



長期追蹤特定藥物

MICROMEDEX® 2.0 | 移動

[我的訂閱](#) | [MICROMEDEX 簡道](#) | [登出](#) | [說明](#)

工具: [藥物相互作用](#) | [Trissel's™ 2 IV 相容性](#) | [藥物鑒定](#) | [Tox 和藥物產品查找](#) | [藥物比較](#) | [RED BOOK Online®](#) | [計算器](#) | [處方集](#) | [CareNotes®](#) | [NeoFax® / Pediatrics](#)

輸入一个或多个搜索条件

搜索

[範例搜尋](#)

RED BOOK Online® 搜尋

[轉到自訂表單管理器](#)

按照產品名稱或製造商搜尋處方或處方藥、保健品、散裝化學品、醫療設備或用品。按照產品的特定活性成分或按照特定代碼（例如 NDC、UPC 或 HRI）進行搜尋。

我想按以下項搜尋...

- ☒ 產品名稱
- ☐ 活性成分
- ☐ NDC/HRI/UPC
- ☐ 製造商名稱

輸入搜尋詞:

提交

我想按以下項篩選...

狀態:

- ☒ 作用中
- ☐ 已停用
- ☐ 全部

重新包裝商:

- ☐ 包括重新包裝商
- ☒ 排除重新包裝商



工具:	藥物 相互作用	Trissel's™ IV 相容性	藥物 鑒定	Tox 和藥物 產品查找	藥物 比較	RED BOOK Online®	計算器	處方集	CareNotes®	NeoFax® / Pediatrics
-----	------------	----------------------	----------	-----------------	----------	---------------------	-----	-----	------------	-------------------------

搜索

範例搜尋

RED BOOK Online® 自訂表單管理器

[返回 RED BOOK Online® 搜尋](#)



使用自訂表單管理器創建新表單，或流覽並載入現有表單。

創建新項目

or

選擇檔案 未選擇檔案

載入選定項

[主頁](#) | [聯絡我們](#) | [關於我們](#) | [內容更新](#) | [培訓中心](#) | [保修與免責聲明](#) | [編輯資訊](#) | [使用者指南](#)

COPYRIGHT © 1974-2012 Thomson Reuters. All rights reserved.



THOMSON REUTERS



THOMSON REUTERS

[範例搜尋](#)

RED BOOK Online® 自訂表單管理器編輯



在搜尋欄位中鍵入代碼。選擇項目，然後選擇 按鈕。選擇 按鈕以從表單中刪除項目。選擇「儲存」以儲存更改。選擇「提交」以檢視結果表單。

有效的自訂表單名稱：**"New Custom File"**（儲存並重新載入檔案之後，您的自訂表單名稱將出現。）

輸入 NDC/HRI/UPC:

00071-0155-23	LIPITOR (Parke Davis)	10 mg	90s ea
00071-0155-34	LIPITOR (Parke Davis)	10 mg	5000s ea
00071-0155-40	LIPITOR (Parke Davis)	10 mg	100s ea

產品：

00071-0155-23 LIPITOR
00071-0155-34 LIPITOR
00071-0155-40 LIPITOR





要為自訂表單新增項目，請按照產品名稱、活性成分、代碼或製造商進行搜尋。

有效的自訂表單名稱：**"New Custom File"**（儲存並重新載入檔案之後，您的自訂表單名稱將出現。）

我想按以下項搜尋...

- ☐ 產品名稱
- ☒ 活性成分
- ☐ NDC/HRI/UPC
- ☐ 製造商名稱

我想按以下項篩選...

狀態：

- ☒ 作用中
- ☐ 已停用
- ☐ 全部

重新包裝商：

- ☐ 包括重新包裝商
- ☒ 排除重新包裝商

輸入搜尋詞：

atorvastatin calcium

atorvastatin calcium IN amlodipine besylate/atorvastatin calcium



選擇項目，然後按一下新增按鈕以新增到自訂表單。

有效的自訂表單名稱： "New Custom File" (儲存並重新載入檔案之後，您的自訂表單名稱將出現。)

結果 1 - 50 / 56

Page 1 of 2 執行 | 前面 | 後面

Add	價格變更	新包裝	產品名稱 ▼	活性成分	製造商/分銷商	重新包裝	學名藥	橙皮書代碼	代碼類型	識別碼	劑型	強度	用法	包裝大小	單位測量
☐			ATORVASTATIN CALCIUM	atorvastatin calcium	APOTEX CORP.	N	Y	AB	NDC	60505-2580-09	TAB	40 mg	ORAL	90s ea	N
☐			ATORVASTATIN CALCIUM	atorvastatin calcium	APOTEX CORP.	N	Y	AB	NDC	60505-2578-09	TAB	10 mg	ORAL	90s ea	N
☐			ATORVASTATIN CALCIUM	atorvastatin calcium	APOTEX CORP.	N	Y	AB	NDC	60505-2579-09	TAB	20 mg	ORAL	90s ea	N
☐			ATORVASTATIN CALCIUM	atorvastatin calcium	APOTEX CORP.	N	Y	AB	NDC	60505-2671-09	TAB	80 mg	ORAL	90s ea	N
☐			ATORVASTATIN CALCIUM	atorvastatin calcium	MAJOR PHARMACEUTICALS	N	Y	AB	NDC	00904-6291-61	TAB	20 mg	ORAL	100s ea	Y
☐			ATORVASTATIN CALCIUM	atorvastatin calcium	MAJOR PHARMACEUTICALS	N	Y	AB	NDC	00904-6290-61	TAB	10 mg	ORAL	100s ea	Y
☐		★	ATORVASTATIN CALCIUM	atorvastatin calcium	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0411-01	TAB	40 mg	ORAL	ea	N
☒	\$	★	ATORVASTATIN CALCIUM	atorvastatin calcium	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0409-20	TAB	10 mg	ORAL	100s ea	Y
☐		★	ATORVASTATIN CALCIUM	atorvastatin calcium	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0409-01	TAB	10 mg	ORAL	ea	N
☐		★	ATORVASTATIN CALCIUM	atorvastatin calcium	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0412-01	TAB	80 mg	ORAL	ea	N

51070.

20



RED BOOK Online® 自訂表單管理器編輯



在搜尋欄位中鍵入代碼。選擇項目，然後選擇 按鈕。選擇 按鈕以從表單中刪除項目。選擇「儲存」以儲存更改。選擇「提交」以檢視結果表單。

有效的自訂表單名稱：**"New Custom File"**（儲存並重新載入檔案之後，您的自訂表單名稱將出現。）

輸入 NDC/HRI/UPC:

產品：

[Add Using Other Criteria](#)

00071-0155-23 LIPITOR
00071-0155-34 LIPITOR
00071-0155-40 LIPITOR
51079-0409-20 ATORVASTATIN CALCIUM



提交

儲存



RED BOOK Online® 自訂表單管理器編輯




在搜尋欄位中鍵入代碼。選擇項目，然後選擇 按鈕。選擇結果表單。

有效的自訂表單名稱： **"New Custom File"** (儲存並重新載入檔案)

輸入 NDC/HRI/UPC:

REDBOOKCustomL....rbo





有關自訂表單產品的詳細結果。要新增或刪除項目，請選擇「返回自訂表單」按鈕。

顯示有效自訂表單名稱的結果： "New Custom File" (儲存並重新載入檔案之後，您的自訂表單名稱將出現。)

結果 1-4 / 4

Page 1 of 1 Go | ◀前面 | 後面▶

Details	價格變更	新包裝	產品名稱 ▼	活性成分	製造商/分銷商	重新包裝	學名藥	複皮書代碼	代碼類型	識別碼	劑型	強度	用法	包裝大小	單位劑量	WAC 組合價格	AWP 組合價格	AWP 單價
	\$	★	ATORVASTATIN CALCIUM	atorvastatin calcium	MYLAN INSTITUTIONAL, INC.	N	Y	AB	NDC	51079-0409-20	TAB	10 mg	ORAL	100s ea	Y	30.93	36.79	0.36790
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-40	TAB	10 mg	ORAL	100s ea	Y	393.50	472.20	4.72200
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-23	TAB	10 mg	ORAL	90s ea	N	337.30	404.76	4.49733
			LIPITOR	atorvastatin calcium	PARKE DAVIS, DIVISION OF PFIZER, INC.	N	N	--	NDC	00071-0155-34	TAB	10 mg	ORAL	5000s ea	N	18739.29	22487.15	4.49743



重新載入自訂的選單

MICROMEDEX® 2.0 | 移動

我的訂閱 | MICROMEDEX

工具: 藥物相互作用 | Trissel's™ 2 IV 相容性 | 藥物鑒定 | Tox 和藥物產品查找 | 藥物比較 | RED BOOK Online® | 計算器 | 虛方集 | CareNotes® Pediatrics | NeoFax® /

輸入一个或多个

RED BOOK Online® 自訂表單管理器



使用自訂表單管理器創建新表單，或流覽並載入現有表單。


創建新項目

OR

選擇檔案 未選擇檔案

主頁 | 聯絡我們 | 關於我們 | 內容更新 | 培訓中心 | 保修與免責聲明

©COPYRIGHT © 1974-2012 Thomson Reuters. All rights reserved.



工具: 藥物
相互作用

Trissel's™2
IV 相容性

藥物
鑒定

Tox 和藥物
產品查找

藥物
比較

RED BOOK
Online®

計算器

輸入一个或多个搜索条件

RED BOOK Online® 自訂表單管理器



使用自訂表單管理器創建新表單，或流覽並載入現有表單。

創建新項目

or

選擇檔案

REDBOOKCustomList.rbo

載入選定項

[頁](#) | [聯絡我們](#) | [關於我們](#) | [內容更新](#) | [培訓中心](#) | [保修與免責聲明](#) | [編輯資訊](#) | [使用者指南](#)

©COPYRIGHT © 1974-2012 Thomson Reuters. All rights reserved.



THO



RED BOOK Online® 自訂表單管理器編輯



在搜尋欄位中鍵入代碼。選擇項目，然後選擇  按鈕。選擇  按鈕以從表單中刪除項目。選擇「儲存」以儲存更改。選擇「提交」以檢視結果表單。

有效的自訂表單名稱： "REDBOOKCustomList.rbo"

輸入 NDC/HRI/UPC:

產品：

[Add Using Other Criteria >](#)

00071-0155-23 LIPITOR
00071-0155-34 LIPITOR
00071-0155-40 LIPITOR
51079-0409-20 ATORVASTATIN CALCIUM



提交



儲存








mobileMicromedex



在iOS上也可以使用MICROMEDEX









Android Market

搜尋



Android Market > 醫療 > Micromedex Drug Information

Micromedex Drug Information

Thomson Reuters (Healthcare) Inc.



★★★★★ (11)

安裝

總覽

使用者評論

新功能

權限

說明

Drug Information is a free resource for on-the-go access to the most trusted clinical reference information, providing users the peace-of mind of knowing the information is from Micromedex®.

This application is not a trial. Drug Information contains the industry's most comprehensive drug information and is backed by the same thorough, unbiased editorial process as Micromedex. Now from anywhere, clinical care teams can instantly get information to support confident treatment decisions. An internet connection is not required, allowing for access at anytime from anywhere.




Drug Information contains concise information on 4500+ search terms, covering:

詳細說明

按一下這裡將這些文字翻譯成您使用的語言。

造訪開發人員的網站 >

應用程式螢幕擷取畫面



+1 1

Tweet

關於這個應用程式

評分：
★★★★★
(11)

已更新：
八月 1, 2011

目前版本：
1.1.19

ANDROID 最低版本
需求：
2.2 以上

類別：
醫療

安裝次數：
500 - 1,000

最近 30 天

大小：
10M

價格：
免費應用程式

內容分級：
所有人

2011 August 4th

Android Market正式上架

我的 Market 帳戶 |

中文 (繁體中文)

說明

